Nav: Home

Scientists opening the door to a new era of medicinal chemistry

July 11, 2019

July 11, 2019 - Progress in the pharmaceutical industry depends largely on the achievements and advances in medicinal chemistry. Big pharma companies, which set the pace of the industry, can be regarded as major drivers of medicinal chemistry evolution. Since 2007 there has been a significant decline in the number of patent records involving new chemical entities, and many molecules observed during the HTS (High Throughput Screening) boom, were not considered attractive. Despite this, dominant methods and principles of organic chemistry have drastically evolved and resulted in building molecules with an increased 3D complexity.

Now, a team of researchers from the Medicinal Chemistry Department of Insilico Medicine have introduced the original descriptor MCE-18, which defines key features of "next-generation" molecules and traces the evolution of medicinal chemistry through the years.

Yan Ivanenkov, Head of Medicinal Chemistry Department at Insilico Medicine, along with Bogdan Zagribelnyy, and Vladimir Aladinskiy, both scientists in the Medicinal Chemistry Department of Insilico Medicine, reported their findings on MCE-18 in the paper, "Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?" in the Journal of Medicinal Chemistry.

MCE-18 can be applied to assess the effectiveness of new molecules and may help researchers in designing new chemical entities that have great potential in modern drug development.

"Equipped with the newly developed MCE-18 descriptor and in silico tools, we have clearly shown that molecules and scaffolds are becoming increasingly sophisticated with higher degrees of 3D complexity for compounds against various biological targets such as kinases, GPCRs and proteases. Pharma has become more qualitative and smarter. We can reasonably regard this as a novel turning point in chemical evolution and state that medicinal chemistry has ushered in a new era of drug design and development" said Ivanenkov.
-end-
For further information, images or interviews, please contact:

Contact: Klug Gehilfe
ai@pharma.ai

Please follow the link to read the article: https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00004

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for the generation of novel molecular structures for diseases with a known target and with no known targets. In addition to collaborating with large pharmaceutical companies, the Insilico is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan Award accompanied with the industry brief. Website: http://insilico.com/

InSilico Medicine, Inc.

Related Evolution Articles:

Chemical evolution -- One-pot wonder
Before life, there was RNA: Scientists at Ludwig-Maximilians-Universitaet (LMU) in Munich show how the four different letters of this genetic alphabet could be created from simple precursor molecules on early Earth -- under the same environmental conditions.
Catching evolution in the act
Researchers have produced some of the first evidence that shows that artificial selection and natural selection act on the same genes, a hypothesis predicted by Charles Darwin in 1859.
Guppies teach us why evolution happens
New study on guppies shows that animals evolve in response the the environment they create in the absence of predators, rather than in response to the risk of being eaten.
Undercover evolution
Our individuality is encrypted in our DNA, but it is deeper than expected.
Evolution designed by parasites
In 'Invisible Designers: Brain Evolution Through the Lens of Parasite Manipulation,' published in the September 2019 issue of The Quarterly Review of Biology, Marco Del Giudice explores an overlooked aspect of the relationship between parasites and their hosts by systematically discussing the ways in which parasitic behavior manipulation may encourage the evolution of mechanisms in the host's nervous and endocrine systems.
More Evolution News and Evolution Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...